Home Companies Catalysts Deep Dives
Padcev enfortumab vedotin APPROVED
Drug Profile
ModalityADC
RouteIV
Therapy AreaOncology
Launch2019-12-18
US LOE2037-07-15
Peak Sales Est$4000M
Formulations[{"id":"padcev-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Days 1,8,15 of 28-day cycle
Companies
PFE (CO_DEVELOPER)50%
ALPMY (ORIGINATOR)50%
Mechanism: Nectin-4-directed (MMAE payload)
Expert: Nectin-4-directed ADC with MMAE payload for urothelial carcinoma.
Everyday: Antibody that delivers chemotherapy to bladder cancer cells.
Targets: ["NECTIN-4"]
Revenue History
PeriodRevenue ($M)
FY2023$723M
FY2024$1,094M
H1 FY2025$683M
Programs (3)
IndicationStageKey StudyRegional Status
Locally advanced/metastatic UC 1LAPPROVEDEV-302[{"stage":"APPROVED","region":"US","approval_date":"2023-12-15"}]
Locally advanced/metastatic UC 2L+APPROVEDEV-301[{"stage":"APPROVED","region":"US","approval_date":"2021-07-09"}]
Muscle-invasive bladder cancer perioperativeAPPROVEDEV-304 (KEYNOTE-B15)[{"stage":"APPROVED","region":"US","approval_date":"2025-11-15"}]
Upcoming Catalysts (2)
PADCEV + Keytruda - MIBC - Japan sNDA Filed Jan 30, 2026
PADCEV + Keytruda - Cis-Ineligible MIBC - EMA Approval 2026
Notes
Bladder cancer ADC. New SoC in 1L with Keytruda. Partnered with Pfizer (Seagen acquisition).
Data from Supabase · Updated 2026-03-24